Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (SHA:600196)
China
· Delayed Price · Currency is CNY 25.72
-0.19 (-0.73%)
Mar 9, 2026, 3:00 PM CST
SHA:600196 Ratios and Metrics
Market cap in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | Current | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2019 - 2015 |
|---|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 6, 2026 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2019 - 2015 |
| Market Capitalization | 63,306 | 59,749 | 61,592 | 86,922 | 113,862 | 125,791 | Upgrade
|
| Market Cap Growth | 7.18% | -2.99% | -29.14% | -23.66% | -9.48% | 93.27% | Upgrade
|
| Enterprise Value | 99,308 | 90,784 | 89,228 | 110,109 | 134,998 | 147,717 | Upgrade
|
| Last Close Price | 25.72 | 24.56 | 24.46 | 33.95 | 46.54 | 51.04 | Upgrade
|
| PE Ratio | 20.78 | 21.57 | 25.82 | 23.30 | 24.08 | 34.34 | Upgrade
|
| Forward PE | 34.76 | 21.15 | 21.49 | 19.36 | 20.43 | 30.68 | Upgrade
|
| PS Ratio | 1.60 | 1.46 | 1.49 | 1.98 | 2.92 | 4.15 | Upgrade
|
| PB Ratio | 1.04 | 1.00 | 1.09 | 1.61 | 2.35 | 2.74 | Upgrade
|
| P/TBV Ratio | 2.75 | 2.73 | 2.89 | 3.99 | 5.83 | 6.40 | Upgrade
|
| P/FCF Ratio | 197.63 | 894.58 | - | - | - | - | Upgrade
|
| P/OCF Ratio | 12.99 | 13.35 | 18.04 | 20.61 | 28.92 | 48.76 | Upgrade
|
| PEG Ratio | - | 1.02 | 1.02 | 1.02 | 1.02 | 2.05 | Upgrade
|
| EV/Sales Ratio | 2.51 | 2.21 | 2.15 | 2.51 | 3.46 | 4.87 | Upgrade
|
| EV/EBITDA Ratio | 18.75 | 16.47 | 22.98 | 19.87 | 32.27 | 36.18 | Upgrade
|
| EV/EBIT Ratio | 40.42 | 30.53 | 75.34 | 32.19 | 53.22 | 56.42 | Upgrade
|
| EV/FCF Ratio | 310.02 | 1359.25 | - | - | - | - | Upgrade
|
| Debt / Equity Ratio | 0.60 | 0.60 | 0.62 | 0.56 | 0.53 | 0.52 | Upgrade
|
| Debt / EBITDA Ratio | 6.93 | 6.07 | 8.44 | 5.25 | 5.86 | 5.63 | Upgrade
|
| Debt / FCF Ratio | 114.65 | 539.31 | - | - | - | - | Upgrade
|
| Net Debt / Equity Ratio | 0.38 | 0.33 | 0.34 | 0.24 | 0.23 | 0.26 | Upgrade
|
| Net Debt / EBITDA Ratio | 4.76 | 3.61 | 5.01 | 2.35 | 2.60 | 2.94 | Upgrade
|
| Net Debt / FCF Ratio | 72.49 | 297.96 | -10.12 | -7.79 | -10.53 | -6.47 | Upgrade
|
| Asset Turnover | 0.34 | 0.36 | 0.38 | 0.44 | 0.44 | 0.38 | Upgrade
|
| Inventory Turnover | 2.91 | 2.90 | 3.01 | 3.77 | 3.82 | 3.03 | Upgrade
|
| Quick Ratio | 0.66 | 0.68 | 0.73 | 0.78 | 0.75 | 0.71 | Upgrade
|
| Current Ratio | 0.92 | 0.92 | 1.00 | 1.06 | 1.04 | 1.01 | Upgrade
|
| Return on Equity (ROE) | 6.75% | 6.03% | 5.23% | 7.70% | 10.55% | 9.25% | Upgrade
|
| Return on Assets (ROA) | 1.32% | 1.61% | 0.67% | 2.13% | 1.79% | 2.05% | Upgrade
|
| Return on Invested Capital (ROIC) | 2.44% | 3.21% | 1.47% | 4.67% | 3.56% | 4.04% | Upgrade
|
| Return on Capital Employed (ROCE) | 3.00% | 3.70% | 1.50% | 4.60% | 4.00% | 4.50% | Upgrade
|
| Earnings Yield | 5.19% | 4.64% | 3.87% | 4.29% | 4.15% | 2.91% | Upgrade
|
| FCF Yield | 0.51% | 0.11% | -3.12% | -1.92% | -0.91% | -1.48% | Upgrade
|
| Dividend Yield | 1.24% | 1.30% | 1.10% | 1.24% | 1.20% | 0.84% | Upgrade
|
| Payout Ratio | 63.02% | 74.35% | 102.89% | 63.64% | 40.48% | 50.09% | Upgrade
|
| Buyback Yield / Dilution | 1.39% | -0.02% | -2.40% | -1.74% | - | - | Upgrade
|
| Total Shareholder Return | 2.63% | 1.28% | -1.29% | -0.50% | 1.20% | 0.84% | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.